Dermatomyositis Dm clinical trials

Explore recruiting dermatomyositis dm clinical trials.

Recruiting dermatomyositis dm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dermatomyositis Dm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis

Greece, Poland, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) – The RECLAIIM Study

Hungary, France, Italy, Spain, Germany, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

Slovakia, Sweden, France, Germany, Czechia, Netherlands +13 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Efficacyand Safety Study Of Daxdilimab Subcutaneous Injection In Adult Participants With Inadequately Controlled Dermatomyositis Or Anti-Synthetase Inflammatory Myositis

Spain, Italy, Germany, Czechia, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Effect of Renal Impairment on Enpatoran Pharmacokinetics

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

Spain, Poland, Hungary, Bulgaria, Italy, Netherlands +8 more

Human Pharmacology (Phase I)- Other EU CTIS Study details

Dermatomyositis Dm trials by city

Dermatomyositis Dm in Toronto Dermatomyositis Dm in Vancouver Dermatomyositis Dm in Montreal Dermatomyositis Dm in Calgary Dermatomyositis Dm in Edmonton Dermatomyositis Dm in Ottawa Dermatomyositis Dm in Winnipeg Dermatomyositis Dm in Quebec City Dermatomyositis Dm in Hamilton Dermatomyositis Dm in Kitchener Dermatomyositis Dm in London Dermatomyositis Dm in Halifax Dermatomyositis Dm in New York Dermatomyositis Dm in Los Angeles Dermatomyositis Dm in Chicago Dermatomyositis Dm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease